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Abstract
Background: 22q11.2 microdeletion is responsible for the DiGeorge Syndrome, characterized by heart defects,
psychiatric disorders, endocrine and immune alterations and a 1 in 4000 live birth prevalence. Real-time
quantitative PCR (qPCR) approaches for allelic copy number determination have recently been investigated in
22q11.2 microdeletions detection. The qPCR method was performed for 22q11.2 microdeletions detection as a first-
level screening approach in a genetically unknown series of patients with congenital heart defects. A technical
issue related to the VPREB1 qPCR marker was pointed out.
Methods: A set of 100 unrelated Italian patients with congenital heart defects were tested for 22q11.2
microdeletions by a qPCR method using six different markers. Fluorescence In Situ Hybridization technique (FISH)
was used for confirmation.
Results: qPCR identified six patients harbouring the 22q11.2 microdeletion, confirmed by FISH. The VPREB1 gene
marker presented with a pattern consistent with hemideletion in one 3 Mb deleted patient, suggestive for a long
distal deletion, and in additional five non-deleted patients. The long distal 22q11.2 deletion was not confirmed by
Comparative Genomic Hybridization. Indeed, the VPREB1 gene marker generated false positive results in association
with the rs1320 G/A SNP, a polymorphism localized within the VPREB1 marker reverse primer sequence. Patients
heterozygous for rs1320 SNP, showed a qPCR profile consistent with the presence of a hemideletion.
Conclusions: Though the qPCR technique showed advantages as a screening approach in terms of cost and time,
the VPREB1 marker case revealed that single nucleotide polymorphisms can interfere with qPCR data generating
erroneous allelic copy number interpretations.
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Background
Real-time quantitative PCR (qPCR) performed with
standard curves has been proposed as a routine, reliable
and highly sensitive assay for gene expression analysis
[1]. qPCR applications are as well becoming a reference
method, alternative to Southern blot and Fluorescence
In Situ Hybridization (FISH), for the measurement of
gene copy number in human tumours with allelic imbal-
ances [2]. Similar applications have been finally adopted
for constitutional allelic copy number determination
with several examples in the detection of 22q11.2 micro-
deletions responsible for the homonymous syndrome,
also known as DiGeorge syndrome (DGS; OMIM
188400) [3-7]. DGS encompasses a wide spectrum of
clinical features with variable expression including dys-
morphic facies, palate abnormalities, congenital cono-
truncal cardiac defects, endocrine dysfunctions, T-cell
mediated immune deficiency and psychiatric disorders
[8]. This autosomal dominant disorder constitutes a
breeding ground for the development of a real-time
qPCR based technique because of its frequency (1:4000
live births) and its allelic heterogeneity. Indeed, the DGS
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microalterations at the same locus including the most
frequent 3 Mb deletion and the smaller nested 1.5 Mb
deletion, occurring respectively in approximately 90%
and 7% of patients with a 22q11.2 anomaly, and other
atypical and rare microdeletions and microduplications
affecting the critical 3 Mb region and its proximal and
distal flanking regions [9].
The specific qPCR analysis for the 22q11.2 region alle-
lic copy number determination performed with SYBR
Green chemistry has been described by Weksberg [6]. It
based on the comparison among the amplifications of
10 different markers localized within the deletion critical
22q11.2 sequence and its proximal regions affected with
rare recently described distal deletions [9]. As the SYBR
Green molecule is a fluorescent non-specific intercalant
agent, the primers design represents the essential point
for the method specificity. The qPCR primers were
designed within regions of unique sequence avoiding the
complex repetitive regions, possibly within gene exons
sequences [6,7].
The qPCR method was previously proposed as a sensi-
tive technique for precise deletion breakpoints definition
with theoretical useful applications in genotype-pheno-
type correlation studies [6,7]. Indeed, the qPCR approach
could be applied to patients with an evident syndromic
phenotype who are not diagnosed with clinical standard
cytogenetic methods due to atypical alterations. Consider-
ing its intrinsic technical advantages, we tested the Weks-
berg qPCR method for 22q11.2 microdeletion detection
as a first-level screening technique exploitable for wide
population studies and useful as screening approach to
the high-resolution cytogenetic tools such as Comparative
Genomic Hybridization (CGH) arrays.
In the present study the Weksberg’s qPCR approach
for 22q11.2 microdeletion detection was performed in a
wide genetically unknown series characterized by a phe-
notypic trait (congenital heart defects) included in DGS
clinical features. A technical issue related to the
VPREB1 qPCR marker was pointed out.
Results
Real-time quantitative PCR results
Eighty-eight patients presented a qPCR markers profile
similar to that observed in del22q11.2 negative control
samples indicating no loss in allelic copy number.
Six patients, five unrelated and a homozygotic twin,
harboured a microdeletion as they showed a qPCR mar-
kers combination suggestive of a long distal deletion. In
these patients D22S181 and VPREB1 amplifications were
consistent with the presence of two allelic copies,
whereas the amplification profile of PRODH, TUPLE1,
COMT and D22S936 indicated a loss of one allelic copy.
Presence of microdeletions was confirmed in all the
six patients with a standard FISH analysis.
An unexpected result from the patients screening was
the finding in five patients of qPCR marker profiles
characterized by the only VPREB1 hemideletion, sugges-
tive for the presence of atypical distal deletions. One
further patient (patient no.4 in Table 1; index case)
showed a qPCR set with hemideletion in the PRODH,
TUPLE1, COMT, D22S936 and VPREB1 markers that
could be consistent with a long atypical deletion.
VPREB1 marker standard curves and melting curves
analysis performed in all subjects presenting the VPREB1
marker hemideletion was consistent with the 10
del22q11.2 negative controls profile thus indicating no dif-
ference in primer efficiency and amplicon specificity.
Fluorescence in situ hybridization and Array CGH on
index case DNA
Standard FISH analysis confirmed the presence of a
microdeletion in the 22q11 region in the index case. The
patient’s DNA was further investigated by CGH assay to
test the qPCR-based deletion extension hypothesis.
Array CGH revealed a heterozygous deletion on
chromosome 22q11.21 spanning at least 2.56 Mb
(chr22: 17,274,835-19,835,417, hg18; chr22: 18,894,835-
21,505,417, hg19 UCSC) (Figure 1). The centromeric
breakpoint maps between probe A_16_P41477672 and
probe A_16_P41477688 (Chr22: 17,270,271-17,274,894 bp,
UCSC, hg18; chr22: 18,890,271-18,894,894, hg19 UCSC)
in LCR22-2, whereas the distal breakpoint maps between
probe A_16_P41484416 and probe A_16_P03603092
(Chr22: 19,835,358-19,891,514 bp, UCSC, hg18; chr22:
21,505,358-21,561,514, hg19 UCSC) in LCR22-4. CGH
assay confirmed the presence of the classical deletion. Nor
the critical region distal probes nor the specific VPREB1
probe (Figure 2, line D) of the CGH-array showed the pre-
sence of a hemideletion in VPREB1 gene or in its proximal
region.
VPREB1 genotype results
VPREB1 gene sequence analysis performed with Set 1
p r i m e r s( T a b l e1a n dF i g u r e2 ,l i n eC )o nt h es i xs u b -
jects with hemideletion in VPREB1 marker showed the
presence of heterozygosity for the rs1320 A/G SNP, a
rare (minor allele frequency in the European Population
=0 . 0 6 2 )m i s s e n s es i n g l en u c l e o t i d ep o l y m o r p h i s m[ 1 0 ]
localized within the complementary region of the qPCR
VPREB1 marker reverse primer. This finding was consis-
tent with the interpretation of the qPCR VPREB1 mar-
ker hemideletions as false positive results.
The subsequent sequencing with Set 2 primers
(Table 2 and Figure 2, line C) of the remaining 94 sub-
jects with a qPCR VPREB1 marker were consistent with
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all patients were homozygous carriers of the rs1320
ancestral G allele.
No immunological disorder was found to be associated
with the rs1320 A allele.
Discussion
The real-time quantitative PCR approach could repre-
sent a robust, fast and accurate assay for the detection
of copy number alterations in genomic DNA [2-7]. Two
peculiar advantages of the qPCR method have been
focused: the detection of atypical microdeletions undiag-
nosed by diagnostic standard FISH approach and the
accurate mapping of deletion breakpoints. Previous stu-
dies on the real-time quantitative application to 22q11.2
microdeletions detection [6,7] were performed in small
series with a previous cytogenetic analysis positive for
22q11.2 microdeletions, as the main purpose was the
refinement of the deletion breakpoints maps with
the increasing of the number of markers in the 22q11.2
deleted region.
In the present study, we performed the qPCR method
in a large paediatric genetically unknown patient cohort
screening. We selected a reduced number of 22q11.2
region markers to provide a rapid patient genotype. The
six markers effectively identified and differentiated the
Table 1 Overview of the qPCR markers results
Patients No. 22q11.2 region qPCR markers results (ΔKCt)
D22S181 PRODH TUPLE1 COMT D22S936 VPREB1
Not deleted 88 0.007 ± 0.123 -0.009 ± 0.006 -0.018 ± 0.076 0.039 ± 0.009 -0.002 ± 0.062 0.082 ± 0.008
22q11.2
hemideletion
6 -0.004 ± 0.140 -0.982 ± 0.039 -1.076 ± 0.014 -0.958 ± 0.154 -0.887 ± 0.047 0.080 ± 0.024
Patient no.4 1 0.106 ± 0.014 -0.992 ± 0.025 -1.037 ± 0.069 -0.994 ± 0.104 -0.918 ± 0.001 -1.050 ± 0.186
VPREB1 hemideletion 5 0.067 ± 0.087 0.005 ± 0.098 0.038 ± 0.095 0.005 ± 0.115 0.020 ± 0.110 -1.093 ± 0.042
Data are expressed as the mean ΔKCt ± standard deviation calculated on all the subjects of each patients set. ΔKCt consistent with a loss of one allelic copy are
indicated in bold.
Figure 1 Array CGH profile of index case DNA. A) Whole chromosome 22 array profile is shown. Scattered plot analysis reveals a deletion in
22q22.12 (horizontal shift to left of 0). B) Zoomed-in gene view of panel A which focuses on a 5.2 Mb window within 22q22.12 containing the
deletion. Each point represents a single probe. Log2 (ratio) was plotted for all oligonucleotide probes based on their chromosome positions.
Aberration calls identified by ADM-2 algorithm (coloured shaded areas) are shown.
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microdeletions) and the rare atypical microdeletions.
Our results confirmed the efficiency of the method in
an unselected series of young patients with congenital
heart defects, identifying six patients harbouring the
classic 3 Mb microdeletion fully concordant with
the FISH analysis results. Interestingly, this approach
provided DGS diagnosis in patients with atypical mild
clinical presentations, extending the accuracy of the
diagnosis and allowing genetic counselling.
At variance with the data presented by Weksberg et al.
[6,7], the VPREB1 qPCR marker analysis produced
results suggestive for the presence of distal deletions at
an unexpected high frequency. Nonetheless, the long
extension of the deletion was not confirmed by the
CGH analysis. Investigating the molecular basis of these
discrepancies, we considered that the VPREB1 gene
sequence is characterized by a high frequency of SNPs
and that the Weksberg’sq P C RVPREB1 marker reverse
primer sequence was specifically designed for the exon
2 VPREB1 sequence containing the rs1320 SNP G
ancestral allele.
Our data suggested that the presence in heterozygosity
of the rs1320 A allele constitutes a critical mismatch in
the reverse primer sequence leading to an inefficient pri-
mer annealing and a consequent misamplification.
Indeed, under these assumptions, patients with an het-
erozygous profile for rs1320, that are carriers of a single
fully complementary allelic copy for qPCR VPREB1 mar-
ker amplification, should produce, as detected in our
experience, a ΔKCt value range similar to that owned by
patients with a constitutional single allelic copy due to
microdeletion. This hypothesis resembles similar experi-
ences previously described [11,12].
Conclusions
The VPREB1 qPCR marker case here described under-
s c o r e dt h ee f f e c to fas i n g l en u c l e o t i d es u b s t i t u t i o ni n
the primer complementary sequence that can lead to an
Table 2 Sequences and locations of VPREB1 PCR
amplification primers
Primer
Sets
Primer Sequences Amplicon
Size
Genomic Location of
Amplicon
Set 1 AGAGCTCTGCATGTCTGCAC 695 22599205-22599900
(Chr 22)
TTCCCTAATGCAGTCTCCAA
Set 2 TCCTGCTCATGCTGTTTGTC 487 22599242-22599729
(Chr 22)
CTGCAGTGGGTTCCATTTCT
Figure 2 Schematics of the VPREB1 gene 22q11.2 region. A) Genomic sequence of VPREB1 gene. B) VPREB1 mRNA sequence (NM_007128.2),
intron sequence was represented with a black line, dotted ends indicated untranslated regions. C) PCR products resulting from Set 1 and Set
2 primers amplification. D) CGH-array VPREB1 probe. E) VPREB1 Weksberg’s primers and relative qPCR product. F) Locations of SNPs, the rs1320
polymorphism is highlighted with a (*). For A-E, the number on the right indicates the base pairs present in each relative segment.
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copy number interpretation. From this observation we
take advantage to stress the relevance of the primer
design for any kind of real-time PCR using standard
curves analysis. Primer sequences should be designed
avoiding both the repeated sequence regions and the
high polymorphic loci.
Finally, data here presented highlighted how this
qPCR method could be a rapid, cost-effective and easy
to reproduce assay for 22q11.2 region genotyping when
applied with a confined number of markers on a high-
throughput system. These advantages are desirable for
an efficient first-level screening approach. We feel that
the qPCR approach could represent a valid alternative
to the more classical and expensive cytogenetic analysis,
and therefore a helpful clinical tool for the 22q11
screening in patients with a non-classic phenotype.
Methods
Subjects
qPCR method was adopted for the screening of a retro-
spective cohort of 100 consecutive unrelated Italian pae-
diatric patients [48 females, 52 males; 6.51 (4.48-9.06)
years (median age, IQ range)] referred to the Paediatric
Cardiac Surgery Unit of the IRCCS Policlinico San
Donato between 2007 and 2009 for the management of
congenital heart defects. The congenital heart defects
were: atrial septal defects (28%), ventricular septal
defects (20%), patent ductus arteriosus (15%), aortic
coartations (14%), Tetralogy of Fallot (12%), miscella-
neous uncommon lesions (11%). Patients affected with
known genetic syndrome were excluded. The genetic
study was adherent to the principles of Helsinki
Declaration. Parents of all participants signed an
informed consent for genetic testing.
Real-time quantitative PCR (qPCR)
Genomic DNA was extracted using standard procedures
from EDTA-blood samples collected from patients at
the time of admission after an overnight fasting. Real-
time quantitative PCR analysis was performed with
the D22S181, PRODH, TUPLE1, COMT, D22S936 and
VPREB1 markers to obtain an immediate overview of
the patient genotype (Figure 3). Primer sequences were
derived from Weksberg studies [6,7]. Though the mar-
ker sets used in the present study were reduced from
those reported by Weksberg [6,7], the efficient discrimi-
nation of the two most frequent alterations, the 3 Mb
and the 1.5 Mb hemizygous deletions, and the detection
of atypical deletions were ensured. G6PDH and HEM3
markers were also amplified for the subsequent data
normalization.
Real-time qPCR assays were performed in a 25 μl reac-
tion volume containing 12.5 μl 2× SYBR Green I PCR
Master Mix (Applied Biosystems, Foster City, CA, USA),
10 ng genomic DNA, forward and reverse primers at final
concentration of 800 nM for the specific 22q11.2 region
markers and 400 nM for G6PDH and HEM3 markers.
Reactions were performed in 96-well MicroAmp Optical
Reaction Plates (Applied Biosystems) using the ABI Prism
7900 high-throughput sequence detection systems
(Applied Biosystems) and data were processed by the asso-
ciated SDS software version 2.3 (Applied Biosystems).
Standard curves for all the primers set used were gener-
ated with series of log dilution of 4 del22q11.2 negative
samples genomic DNA. Slopes derived from standard
curves were used for data normalization following Weks-
berg’s instructions [6]. Reaction specificity was confirmed
with melting curves analysis and agarose gel electrophor-
esis experiments. Each qPCR assay included at least 3
del22q11.2 negative control samples; all reactions were
performed in triplicate, with replicates being performed on
different days. Allelic copy number of the 22q11.2 region
markers where finally determined with the comparison of
normalized data of control samples and patients. Final
ΔKCt values were considered as follows: the interval -0.75
to -1.25 indicated loss of one copy (presence of hemizy-
gous microdeletion), whereas a ratio of 0.00 ± 0.25 corre-
sponded to two allelic copies (no microdeletion). Data
normalization and allelic copy number equations were
derived from Weksberg’s studies [6,7].
Figure 3 Representation of Chromosome 22 with enlargement
of the 22q11.2 region and qPCR markers locations. qPCR
markers localization was shown with respect to the two most
classical 3 Mb and 1.5 Mb microdeletions and two different
examples of atypical deletions. PRODH, TUPLE1 and COMT markers
recognized 3 Mb and 1,5 Mb microdeletions; D22S936 marker
allowed to distinguish between 3 Mb or 1.5 Mb microdeletions;
D22S181 and VPREB1, both localized outside the critical deletion
region, allowed the detection of respectively proximal and distal
atypical microalterations.
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analysis an amplification efficiency similar to that
reported by Weksberg [6], however each standard curve
slope value was found in the 3.32 ± 0.25 range allowing
t h es u c c e s s i v ea m p lification comparison and data ela-
boration. Melting curve analysis and agarose gel-electro-
phoresis assay confirmed the amplicons specificity
showing respectively a single peak on the dissociation
curve plot and a single band of the expected size on the
electrophoretic run. qPCR results for this study series
are summarized in Table 1.
Fluorescence in situ hybridization analysis
The FISH technique was performed on peripheral blood
lymphocytes according to the manufacturer’si n s t r u c -
tion. A commercial probe results in the simultaneous
labelling of the 22q11.2 chromosome region that
includes TUPLE1 gene also known as HIRA gene (red
labelling) and the terminal region of chromosome 22 as
control (green labelling) was used. Twenty patient’s
metaphases were analyzed under a fluorescence micro-
scope (Leica Microsystem, Wetzlar, Germany).
Array CGH analysis
For CGH, genomic DNA was extracted from proband’s
blood using the Genelute Blood Genomic DNA Kit
(Sigma-Aldrich Corp. St. Louis, MO, USA) according to
the manufacture’s instructions. Pooled DNA from the
peripheral blood of 10 healthy donors (Promega, Madi-
son, WI), sex-matched to the sample was used as a
reference for the DNA extracted from peripheral blood.
Genomic DNA (1.5 μg) was hybridized to the 244 KB
microarray (Agilent Technologies, Palo Alto, CA, USA),
consisting of ~236,000 60-mer oligonucleotide probes
covering the entire genome at the average spatial resolu-
tion of ~30 Kb, and processed according to the manu-
facturer’s instructions.
The dye emission capture was performed by a dual-
laser Agilent Scanner. Images were extracted using Agi-
lent Feature Extraction software 9.1 and analysed by
DNA Analytics 4.0 software. A log ratio plot between
test and reference genomic DNA was assigned such that
aberrations in test DNA copy number at a particular
locus are observed as the deviation of the ratio plots
from a modal value of 0; aberration calls was identified
by the ADM-2 algorithm.
VPREB1 Sequencing
VPREB1 amplification was performed on all qPCR ana-
lysed samples with the same genomic DNA template
used in qPCR experiments. Two different primers sets
were designed using Primer3 online software [13]. Set 1
amplicon performed the sequencing of the entire
VPREB1 gene, while Set 2 amplicon was centred within
the qPCR marker reverse primer sequence (Figure 2).
Primer sequences are shown in Table 2.
PCR was performed in a 25 μl reaction volume con-
taining 200 ng genomic DNA, 2.5 U Platinum Taq DNA
Polymerase (Invitrogen, Madison, WI, USA), 25 μmol of
each primer, 100 μmol/L of each dNTP, 1× PCR buffer
(Invitrogen) and 1.5 mM MgCl2 with the use of a MyCy-
cler thermal cycler (Biorad, Hercules, CA, USA). Cycling
variables were as follows: 94°C for 5 min (first denaturing
step); 30 cycles of 94°C for 1 min, 56.3°C for 1 min and
72°C for 2 min; and 72°C for 10 min (last extension
step). We did bidirectional sequencing of the purified
PCR products (GE Healthcare, Buckinghamshire, UK) by
a BigDye terminator sequencing kit (Applied Biosystems)
and a 3100 genetic analyser (Applied Biosystems).
Sequences were analysed by the ABI Prism Sequencing
Analysis Software (version 3.7, Applied Biosystems).
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